Chemotherapy Effects - Pipeline Review, Q1 2011

Description: Chemotherapy Effects - Pipeline Review, Q1 2011

Summary

Global Markets Direct's, 'Chemotherapy Effects - Pipeline Review, Q1 2011', provides an overview of the Chemotherapy Effects therapeutic pipeline. This report provides information on the therapeutic development for Chemotherapy Effects, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chemotherapy Effects. ‘Chemotherapy Effects - Pipeline Review, Q1 2011’ is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- A snapshot of the global therapeutic scenario for Chemotherapy Effects.
- A review of the Chemotherapy Effects products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chemotherapy Effects pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Effects.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chemotherapy Effects pipeline depth and focus of Chemotherapy Effects therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chemotherapy Effects Overview
Therapeutics Development
An Overview of Pipeline Products for Chemotherapy Effects
Chemotherapy Effects Therapeutics under Development by Companies
Chemotherapy Effects Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Chemotherapy Effects Therapeutics Development
Sanofi-Aventis
Adherex Technologies Inc.
Merck & Co., Inc.
Archimedes Pharma Limited
Aphios Corporation
Daewoong Pharmaceutical Co., Ltd.
GTx, Inc.
Celldex Therapeutics, Inc.
Biovitrum AB
BTG International Ltd
Teikoku Pharma USA, Inc.
SymBio Pharmaceuticals Limited
Spectrum Pharmaceuticals, Inc.
Wellstat Therapeutics Corporation
ARCA biopharma, Inc.
Rottapharm SpA
Indus Biotech Private Limited
Phage Biotechnology Corporation
CeNeRx BioPharma, Inc.
PhytoCeutica, Inc.
Genexine Co., Ltd.
Sound Pharmaceuticals, Inc.
The GI Company, Inc.
Universities/Institutes Involved in Chemotherapy Effects Therapeutics Development
Chemotherapy Effects Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Acapodene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fosaprepitant dimeglumine + Ondansetron + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Glutamine + Calcium + Magnesium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Kepivance - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PN-401 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Human Granulocyte Colony Stimulating Factor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sodium thiosulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Voraxaze - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zindol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Alpha-lipoic acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amifostine Trihydrate for Ovarian Epithelial Cancer (Robert H. Lurie Cancer Center) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aprepitant + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Calcium gluconate + Magnesium sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Candesartan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Capecitabine + Celecoxib + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
carboplatin + glutathione + paclitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CIDEX + Cyclophosphamide + Prednisolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone + Granisetron + Prochlorperazine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Emend - Drug Profile
Product Description
Mechanism of Action
R&D Progress
F511 Cream - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gabapentin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Granisetron + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Granisetron + Dexamethasone + Prochlorperazine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Haloperidol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Loperamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Melphalan + Prednisolone + Cyclophosphamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Metoclopramide + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Octreotide Acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Octreotide Acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Olanzapine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Selenium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vitamin D + Calcium Carbonate + Zoledronic Acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress

Discontinued Products
Chemotherapy Effects - Featured News
Dec 16, 2009: Almac Discovery Announce Commencement Of Phase I Trials Of Granisetron Nasal Spray
Oct 09, 2009: Spectrum Pharmaceuticals Receives Complete Response Letter from FDA for Fusilev in Advanced Metastatic Colorectal Cancer
Dec 11, 2008: Levoleucovorin (Fusilev) Listed in the NCCN Drugs & Biologics Compendium and NCCN Updates Clinical Practice Guidelines in Oncology.
Nov 07, 2008: Fusilev Receives Unique, Product-Specific J-Code from the Centers for Medicare and Medicaid Services (CMS)
Oct 31, 2008: Spectrum Pharmaceuticals Files Supplemental New Drug Application with FDA for Fusilev in Colorectal Cancer
Feb 22, 2007: Valeant Pharmaceuticals Files Investigational New Drug Application for Cesamet
May 31, 2006: CuraGen Initiates Second Phase II Clinical Trial With Velafermin
Appendix
Methodology
Number of Products Under Development for Chemotherapy Effects, 2011
Products under Development for Chemotherapy Effects – Comparative Analysis, 2011
Comparative Analysis by Late Stage Development, 2011
Comparative Analysis by Mid Clinical Stage Development, 2011
Comparative Analysis by Early Clinical Stage Development, 2011
Comparative Analysis by Pre-Clinical Stage Development, 2011
Sanofi-Aventis, 2011
Adherex Technologies Inc., 2011
Merck & Co., Inc., 2011
Archimedes Pharma Limited, 2011
Aphios Corporation, 2011
Daewoong Pharmaceutical Co., Ltd., 2011
GTx, Inc., 2011
Cellidex Therapeutics, Inc., 2011
Biovitrum AB, 2011
BTG International Ltd, 2011
Teikoku Pharma USA, Inc., 2011
SymBio Pharmaceuticals Limited, 2011
Spectrum Pharmaceuticals, Inc., 2011
Wellstat Therapeutics Corporation, 2011
ARCA biopharma, Inc., 2011
Rottapharm SpA, 2011
Indus Biotech Private Limited, 2011
Phage Biotechnology Corporation, 2011
CeNeRx BioPharma, Inc., 2011
PhytoCeutica, Inc., 2011
Genexine Co., Ltd., 2011
Sound Pharmaceuticals, Inc., 2011
The GI Company, Inc., 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Discontinued Products

List of Figures
Number of Products under Development for Chemotherapy Effects, 2011
Products under Development for Chemotherapy Effects – Comparative Analysis, 2011
Products under Development by Companies, 2011
Products under Investigation by Universities/Institutes, 2011
Late Stage Products, 2011
Mid Clinical Stage Products, 2011
Early Clinical Stage Products, 2011
Pre-Clinical Stage Products, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products, 2011
Assessment by Route of Administration, 2011
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Assessment by Stage and Molecule Type, 2011

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Chemotherapy Effects - Pipeline Review, Q1 2011
Web Address: http://www.researchandmarkets.com/reports/1524619/
Office Code: SCD2LP73

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>USD 500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>USD 1000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>USD 1500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ____________________________________________ Last Name: _________________________________________
Email Address: * __________________________________________
Job Title: ____________________________________________
Organisation: __________________________________________
Address: ____________________________________________
City: ____________________________________________
Postal / Zip Code: __________________________________________
Country: ____________________________________________
Phone Number: __________________________________________
Fax Number: __________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World